Differentiated evaluation of intravenous immunoglobulins in patients with recurrent implantation failure in assisted reproductive technology
Journal of obstetrics and women's diseases · 29.12.2025 · 74 (6) · 38-49
DOI: 10.17816/jowd695843 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of obstetrics and women's diseases, online erschienen am 29.12.2025. Verfasst von Ekaterina A. Kornyushina und 7 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Currently, the use of intravenous immunoglobulins in patients with recurrent implantation failure after in vitro fertilization is controversial due to the lack of standard treatment protocols and the heterogeneity of patient selection criteria for this therapy. This study was the first to compare the outcomes of assisted reproductive technology cycles using intravenous immunoglobulin therapy in patients with immunological factors for reproductive failure and chronic endometritis. AIM: The aim of this study was to develop a differentiated approach to the use of intravenous immunoglobulins in patients with recurrent implantation failure in assisted reproductive technology cycles. METHODS: This cohort study included patients with various causes of infertility and at least one unsuccessful embryo transfer who were treated between 2024 and 2025. All patients received immunomodulatory therapy using intravenous immunoglobulins at a dose of 15 g per course. Patients were stratified by the presence of antiphospholipid antibodies and chronic endometritis. The final analysis of the effectiveness of the assisted reproductive technology program included patients with optimal quality embryo transfers. RESULTS: The study included 131 patients. The presence of antiphospholipid antibodies was associated with a higher efficiency of transfer of frozen embryos of optimal quality compared to patients with chronic endometritis (76.0% versus 48.4%, respectively; p = 0.035), which indicates different sensitivity of these clinical phenotypes to intravenous immunoglobulins therapy. CONCLUSION: Immunotherapy with intravenous immunoglobulins is effective as part of combination therapy for patients with immune-related forms of reproductive disorders, particularly in the presence of antiphospholipid antibodies. In chronic endometritis, the efficacy of intravenous immunoglobulins is limited. Further research is needed to optimize their regimens and conditions. Diagnosis and treatment of chronic endometritis are essential before entering assisted reproductive technology programs.
Zitieren
APA
Kornyushina, E. A., Khalenko, V. V., Shipitsyna, E. V., Shengelia, M. O., Sazonova, A. P., Semenov, V. A., Pachuliia, O. V., & Bespalova, O. N. (2025). Differentiated evaluation of intravenous immunoglobulins in patients with recurrent implantation failure in assisted reproductive technology. Journal of obstetrics and women's diseases, 74(6), 38-49. https://doi.org/10.17816/jowd695843
Vancouver
Kornyushina EA, Khalenko VV, Shipitsyna EV, Shengelia MO, Sazonova AP, Semenov VA, et al. Differentiated evaluation of intravenous immunoglobulins in patients with recurrent implantation failure in assisted reproductive technology. Journal of obstetrics and women's diseases. 2025;74(6):38-49. doi:10.17816/jowd695843
BibTeX
@article{Kornyushina2025,
author = {Kornyushina, Ekaterina A. and Khalenko, Vladislava V. and Shipitsyna, Elena V. and Shengelia, Margarita O. and Sazonova, Anastasiia P. and Semenov, Vyacheslav A. and Pachuliia, Olga V. and Bespalova, Olesya N.},
title = {Differentiated evaluation of intravenous immunoglobulins in patients with recurrent implantation failure in assisted reproductive technology},
journal = {Journal of obstetrics and women's diseases},
year = {2025},
volume = {74},
number = {6},
pages = {38--49},
doi = {10.17816/jowd695843}
}
EUVIMED